Overview

Essential Pharma buys mature, low-volume medicines that larger pharma companies divest to keep patients supplied. It acquires at-risk and legacy drugs across rare diseases, CNS, ophthalmology, and gastroenterology, then commercializes and distributes them across about 70 countries, managing complex transfers and licenses to prevent shortages. Its growth comes from strategic acquisitions and licensing deals, such as rights to Iopidine and Methergine and the Renaissance Pharma integration, plus development-stage assets like an immunotherapy for high-risk neuroblastoma. Led by CEO Emma Johnson since 2023, the company aims to expand its portfolio and global reach to sustain access to essential medicines when big firms shift focus.